Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pluri Inc. SEC filings document the governance, capital-structure, listing-status, and material-event disclosures of a biotechnology company using a proprietary cell-based platform. Proxy materials cover annual shareholder meeting matters, director elections, auditor ratification, and board governance.
Pluri’s Form 8-K filings record events such as board composition changes, executive equity awards, Nasdaq Capital Market listing-standard notices and compliance updates, material agreements, shareholder voting matters, and capital-structure disclosures. These filings provide the formal record for corporate actions affecting the company’s common shares, governance framework, and public-company reporting obligations.
Pluri Inc. entered into a securities purchase agreement for a private placement of 625,000 common shares and warrants to purchase up to 625,000 common shares, at a combined price of $4.00 per share and warrant, expected to generate approximately $2.5 million in gross proceeds.
The investor is Chutzpah Holdings LP, a limited partnership beneficially owned by existing shareholder and director Alexandre Weinstein. The warrants are immediately exercisable at $4.25 per share for eighteen months and include a 35% beneficial ownership limitation. Pluri plans to use the funds for working capital and general corporate purposes, with closing expected around the end of April 2026, subject to customary conditions. The securities are being issued in an unregistered offering relying on exemptions under Section 4(a)(2) and/or Regulation S and cannot be sold in the United States without registration or a valid exemption.
Pluri Inc. reports it has regained compliance with Nasdaq’s market value listing standard. Nasdaq notified the company that, for 10 consecutive business days from February 13, 2026 to February 26, 2026, the market value of Pluri’s listed securities was at least $35 million, meeting Listing Rule 5550(b)(2).
Because this requirement is now satisfied, Nasdaq has closed the deficiency matter and Pluri’s shares remain in good standing on The Nasdaq Capital Market. Earlier, Nasdaq had warned Pluri that it did not meet the required market value or the alternative stockholders’ equity or net income standards.
Pluri Inc. reported wider losses and growing liquidity pressure for the six months ended December 31, 2025. Revenue was broadly flat at $514,000 versus $511,000 a year earlier, mainly from CDMO services and AgTech proof-of-concept collaborations.
Net loss rose to $13.0 million from $9.1 million, driven by higher research and development spending of $7.8 million and general and administrative expenses of $5.3 million. Cash, cash equivalents, short-term deposits, restricted cash and restricted bank deposits totaled $13.6 million as of December 31, 2025, against a working capital deficit of $18.5 million and an accumulated deficit of $455.4 million.
The balance sheet is constrained by an EIB loan with principal of $23.5 million and accrued interest of $4.3 million due June 1, 2026, and management acknowledges “substantial doubt” about the company’s ability to continue as a going concern, estimating less than six months of funding from the February 2026 reporting date. Pluri raised $2.5 million in a December 2025 private placement and $300,000 via a SAFE at subsidiary Kokomodo, and received a Nasdaq notice on January 20, 2026 for not meeting the $35 million market value of listed securities requirement.
Pluri Inc. reported that it received a notice from Nasdaq on January 20, 2026 stating that the company no longer meets Nasdaq’s continued listing standards for The Nasdaq Capital Market. Pluri’s market value of listed securities has fallen below the required $35 million, and it also does not meet the alternative standards of at least $2.5 million in stockholders’ equity or $500,000 in net income over the specified periods.
The company’s common shares will continue to trade on Nasdaq under the symbol PLUR during an initial 180‑day compliance period ending on July 20, 2026. Pluri can regain compliance if its market value of listed securities is at or above $35 million for at least 10 consecutive business days, and it is evaluating options to achieve this. If it fails to regain compliance, its shares would be subject to delisting, though the company would have the right to appeal to a Nasdaq Hearings Panel.
Pluri Inc. entered into a securities purchase agreement with Chutzpah Holdings LP, a fund beneficially owned by director Alexandre Weinstein, for a private placement of 625,000 common shares and warrants to purchase up to 625,000 additional shares. The units are priced at $4.00 per share plus warrant, for expected gross proceeds of approximately $2.5 million, with warrants exercisable immediately at $4.25 per share until June 30, 2026 and subject to a 35% beneficial ownership cap. The closing is expected on or about December 15, 2025, subject to customary conditions, and proceeds are earmarked for working capital and general corporate purposes.
The board granted 10,248 restricted stock units to the CEO and CFO and 2,885 RSUs to directors in lieu of cash compensation, vesting monthly over three months to support cost management and align incentives. Effective December 4, 2025, Alexandre Weinstein was appointed Chairman of the Board and Zami Aberman was appointed Vice Chairman, with Aberman’s consultancy agreement ending January 4, 2026.
Pluri Inc. reported that Chief Executive Officer and director Yaky Yanay received a grant of 6,588 restricted stock units of common stock on December 4, 2025, at a price of $0 per share under the company's 2019 Equity Compensation Plan.
The RSUs vest in equal installments on a monthly basis over three months following the grant date. After this award, Yanay beneficially owns 497,758 shares of common stock directly and 836 shares indirectly through Yaacov Yanay Management Ltd.
Pluri Inc. director Rami Avraham Levi reported a stock-based compensation grant on Form 4. On December 4, 2025, he acquired 653 shares of Pluri common stock as restricted stock units at a stated price of $0 per share under the company’s 2019 Equity Compensation Plan. Following this grant, he beneficially owned 18,967 shares of common stock in total. The RSUs were approved by the Board of Directors and are scheduled to vest in equal monthly installments over three months after the grant date, providing short-term, time-based equity incentives linked to continued service.
Pluri Inc. (PLUR) reported insider activity involving director and 10% owner Alexandre Weinstein and his entities Chutzpah Holdings Limited and Plantae Bioscience Ltd. On February 25, 2025, 10,250 common shares were acquired at a price of $0, held directly. On October 29, 2025, 1,002,169 pre-funded warrants with an exercise price of $0.0001 per share were exercised into common stock, resulting in 1,933,415 common shares indirectly held through Chutzpah.
Separately, on April 28, 2025, 452,702 common shares were purchased at $4.61 per share and are indirectly held through Plantae. The filing explains that Chutzpah and Plantae are controlled by Mr. Weinstein, who may be deemed to beneficially own their holdings, while formally disclaiming beneficial ownership beyond his pecuniary interest. It also notes that 84,599 common warrants related to a January 23, 2025 securities purchase agreement are exercisable until June 30, 2028.
Pluri Inc. (PLUR) reported a director’s equity award on a Form 4. On November 12, 2025, the director acquired 11,685 shares of common stock at $0, reflecting a grant of restricted stock units (RSUs) under the company’s 2019 Equity Compensation Plan. Following the transaction, the director beneficially owned 11,685 shares. The RSUs vest over three years: 50% vests ratably on a quarterly basis in the first year, then 25% in the second year and 25% in the third year.
Pluri Inc. reported that its Board granted CEO Yaky Yanay equity awards recognizing 2025 performance. The package includes 39,050 fully vested RSUs and stock options for 39,050 shares, exercisable for three years at an exercise price of $5.00 per share. The Board also approved a contingent award of 9,266 RSUs and options for 9,266 shares, with a grant date upon satisfaction of specified objectives by December 31, 2025, and the options exercisable for three years at $5.00.